The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
IL-1αβ Blockade Prevents Cartilage and Bone Destruction in Murine Type II Collagen-Induced Arthritis, Whereas TNF-α Blockade Only Ameliorates Joint Inflammation
Abstract
Anti-TNF-α treatment of rheumatoid arthritis patients markedly suppresses inflammatory disease activity, but so far no tissue-protective effects have been reported. In contrast, blockade of IL-1 in rheumatoid arthritis patients, by an IL-1 receptor antagonist, was only moderately effective in suppressing inflammatory symptoms but appeared to reduce the rate of progression of joint destruction. We therefore used an established collagen II murine arthritis model (collagen-induced arthritis(CIA)) to study effects on joint structures of neutralization of either TNF-α or IL-1. Both soluble TNF binding protein and anti-IL-1 treatment ameliorated disease activity when applied shortly after onset of CIA. Serum analysis revealed that early anti-TNF-α treatment of CIA did not decrease the process in the cartilage, as indicated by the elevated COMP levels. In contrast, anti-IL-1 treatment of established CIA normalized COMP levels, apparently alleviating the process in the tissue. Histology of knee and ankle joints corroborated the finding and showed that cartilage and joint destruction was significantly decreased after anti-IL-1 treatment but was hardly affected by anti-TNF-α treatment. Radiographic analysis of knee and ankle joints revealed that bone erosions were prevented by anti-IL-1 treatment, whereas the anti-TNF-α-treated animals exhibited changes comparable to the controls. In line with these findings, metalloproteinase activity, visualized by VDIPEN production, was almost absent throughout the cartilage layers in anti-IL-1-treated animals, whereas massive VDIPEN appearance was found in control and sTNFbp-treated mice. These results indicate that blocking of IL-1 is a cartilage- and bone-protective therapy in destructive arthritis, whereas the TNF-α antagonist has little effect on tissue destruction.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ROLE OF CYTOKINES IN RHEUMATOID ARTHRITIS
Feldmann, M., Brennan, F. M., & Maini, R. N. (1996) · Annual Review of Immunology · doi:10.1146/annurev.immunol.14.1.397 · Cited by 2,514
Moreland, L. W., Baumgartner, S. W., Schiff, M. H., Tindall, E. A., Fleischmann, R. M., Weaver, A. L., Ettlinger, R. E., Cohen, S., Koopman, W. J., Mohler, K., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199707173370301 · Cited by 1,622
BRENNAN, F. (1989) · The Lancet · doi:10.1016/s0140-6736(89)90430-3 · Cited by 1,129
Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α
Elliott, M. J., Maini, R. N., Feldmann, M., Long‐Fox, A., Charles, P., Katsikis, P., Brennan, F. M., Walker, J., Bijl, H., Ghrayeb, J., et al. (1993) · Arthritis & Rheumatism · doi:10.1002/art.1780361206 · Cited by 1,038
Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis.
Williams, R. O., Feldmann, M., & Maini, R. N. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.20.9784 · Cited by 989
Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist
Bresnihan, B., Alvaro-Gracia, J. M., Cobby, M., Doherty, M., Domljan, Z., Emery, P., Nuki, G., Pavelka, K., Rau, R., Rozman, B., et al. (1998) · Arthritis & Rheumatism · doi:10.1002/1529-0131(199812)41:12<2196::aid-art15>3.0.co;2-2 · Cited by 981
Arend, W. P., & Dayer, J. (1995) · Arthritis & Rheumatism · doi:10.1002/art.1780380202 · Cited by 891
Joosten, L. A. B., Helsen, M. M. A., van de Loo, F. A. J., & van den Berg, W. B. (1996) · Arthritis & Rheumatism · doi:10.1002/art.1780390513 · Cited by 400
Self-citationLoo, F. A. J. V. D., Joosten, L. A. B., Van Lent, P. L. E. M., Arntz, O. J., & Van Den Berg, W. B. (1995) · Arthritis & Rheumatism · doi:10.1002/art.1780380204 · Cited by 380
Self-citationSAXNE, T., & HEINEGÅRD, D. (1992) · Rheumatology · doi:10.1093/rheumatology/31.9.583 · Cited by 344
Self-citation
Cited by
Tumor necrosis factor antagonist mechanisms of action: A comprehensive review
Tracey, D., Klareskog, L., Sasso, E. H., Salfeld, J. G., & Tak, P. P. (2008) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.10.001 · Cited by 1,628
The IL-1 family: regulators of immunity
Sims, J. E., & Smith, D. E. (2010) · Nature Reviews Immunology · doi:10.1038/nri2691 · Cited by 1,418
Anti-TNFα Therapy of Rheumatoid Arthritis: What Have We Learned?
Feldmann, M., & Maini, R. N. (2001) · Annual Review of Immunology · doi:10.1146/annurev.immunol.19.1.163 · Cited by 1,257
Evidence that cytokines play a role in rheumatoid arthritis
Brennan, F. M., & McInnes, I. B. (2008) · Journal of Clinical Investigation · doi:10.1172/jci36389 · Cited by 1,103
Zhang, Q., Dehaini, D., Zhang, Y., Zhou, J., Chen, X., Zhang, L., Fang, R. H., Gao, W., & Zhang, L. (2018) · Nature Nanotechnology · doi:10.1038/s41565-018-0254-4 · Cited by 958
A clinical perspective of IL‐1β as the gatekeeper of inflammation
Dinarello, C. A. (2011) · European Journal of Immunology · doi:10.1002/eji.201141550 · Cited by 775
The balance between IL-1 and IL-1Ra in disease
Arend, W. P. (2002) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(02)00020-5 · Cited by 721
Anti-TNF-α therapies: the next generation
Palladino, M. A., Bahjat, F. R., Theodorakis, E. A., & Moldawer, L. L. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1175 · Cited by 576
Absence of the P2X7 Receptor Alters Leukocyte Function and Attenuates an Inflammatory Response
Labasi, J. M., Petrushova, N., Donovan, C., McCurdy, S., Lira, P., Payette, M. M., Brissette, W., Wicks, J. R., Audoly, L., & Gabel, C. A. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.12.6436 · Cited by 490
Liacini, A., Sylvester, J., Li, W. Q., & Zafarullah, M. (2002) · Matrix Biology · doi:10.1016/s0945-053x(02)00007-0 · Cited by 403
Fleischmann, R. M., Schechtman, J., Bennett, R., Handel, M. L., Burmester, G., Tesser, J., Modafferi, D., Poulakos, J., & Sun, G. (2003) · Arthritis & Rheumatism · doi:10.1002/art.10870 · Cited by 392
Role of cytokines in rheumatoid arthritis: an education in pathophysiology and therapeutics
Feldmann, M., & Maini, S. R. N. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00626.x · Cited by 381
Prognostic laboratory markers of joint damage in rheumatoid arthritis
Lindqvist, E., Eberhardt, K., Bendtzen, K., Heinegård, D., & Saxne, T. (2005) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2003.019992 · Cited by 367
Self-citationAnakinra for Rheumatoid Arthritis: A Systematic Review
MERTENS, M., & SINGH, J. A. (2009) · The Journal of Rheumatology · doi:10.3899/jrheum.090074 · Cited by 344
Kirkham, B. W., Lassere, M. N., Edmonds, J. P., Juhasz, K. M., Bird, P. A., Lee, C. S., Shnier, R., & Portek, I. J. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21749 · Cited by 336
Critical Roles for Interleukin 1 and Tumor Necrosis Factor α in Antibody-induced Arthritis
Ji, H., Pettit, A., Ohmura, K., Ortiz-Lopez, A., Duchatelle, V., Degott, C., Gravallese, E., Mathis, D., & Benoist, C. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20020439 · Cited by 332
Persistent inflammatory and non-inflammatory mechanisms in refractory rheumatoid arthritis
Buch, M. H., Eyre, S., & McGonagle, D. (2021) · Nature Reviews Rheumatology · doi:10.1038/s41584-020-00541-7 · Cited by 312
Zwerina, J., Hayer, S., Tohidast‐Akrad, M., Bergmeister, H., Redlich, K., Feige, U., Dunstan, C., Kollias, G., Steiner, G., Smolen, J., et al. (2004) · Arthritis & Rheumatism · doi:10.1002/art.11487 · Cited by 307
TNF-induced structural joint damage is mediated by IL-1
Zwerina, J., Redlich, K., Polzer, K., Joosten, L., Krönke, G., Distler, J., Hess, A., Pundt, N., Pap, T., Hoffmann, O., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0610812104 · Cited by 304
Self-citationCoppieters, K., Dreier, T., Silence, K., Haard, H. D., Lauwereys, M., Casteels, P., Beirnaert, E., Jonckheere, H., Wiele, C. V. D., Staelens, L., et al. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21827 · Cited by 303
Selected cytokine pathways in rheumatoid arthritis
Noack, M., & Miossec, P. (2017) · Seminars in Immunopathology · doi:10.1007/s00281-017-0619-z · Cited by 303
Inhibition of toll‐like receptor 4 breaks the inflammatory loop in autoimmune destructive arthritis
Abdollahi‐Roodsaz, S., Joosten, L. A. B., Roelofs, M. F., Radstake, T. R. D. J., Matera, G., Popa, C., van der Meer, J. W. M., Netea, M. G., & van den Berg, W. B. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22848 · Cited by 302
Self-citationHardy, M. M., Seibert, K., Manning, P. T., Currie, M. G., Woerner, B. M., Edwards, D., Koki, A., & Tripp, C. S. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10356 · Cited by 302
Joosten, L. A. B., Netea, M. G., Fantuzzi, G., Koenders, M. I., Helsen, M. M. A., Sparrer, H., Pham, C. T., van der Meer, J. W. M., Dinarello, C. A., & van den Berg, W. B. (2009) · Arthritis & Rheumatism · doi:10.1002/art.25006 · Cited by 296
Self-citationArntz, O. J., Pieters, B. C. H., Oliveira, M. C., Broeren, M. G. A., Bennink, M. B., de Vries, M., van Lent, P. L. E. M., Koenders, M. I., van den Berg, W. B., van der Kraan, P. M., et al. (2015) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201500222 · Cited by 255
Self-citationRegional analysis of p53 mutations in rheumatoid arthritis synovium
Yamanishi, Y., Boyle, D. L., Rosengren, S., Green, D. R., Zvaifler, N. J., & Firestein, G. S. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.152333199 · Cited by 214
Treatment of arthritis with a selective inhibitor of c-Fos/activator protein-1
Aikawa, Y., Morimoto, K., Yamamoto, T., Chaki, H., Hashiramoto, A., Narita, H., Hirono, S., & Shiozawa, S. (2008) · Nature Biotechnology · doi:10.1038/nbt1412 · Cited by 214
Fairweather, D., Frisancho-Kiss, S., Yusung, S. A., Barrett, M. A., Davis, S. E., Gatewood, S. J. L., Njoku, D. B., & Rose, N. R. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63241-5 · Cited by 198
Treatment with an Interleukin 1 beta antibody improves glycemic control in diet-induced obesity
Osborn, O., Brownell, S. E., Sanchez-Alavez, M., Salomon, D., Gram, H., & Bartfai, T. (2008) · Cytokine · doi:10.1016/j.cyto.2008.07.004 · Cited by 160
Eriksson, U., Kurrer, M. O., Sonderegger, I., Iezzi, G., Tafuri, A., Hunziker, L., Suzuki, S., Bachmaier, K., Bingisser, R. M., Penninger, J. M., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20021788 · Cited by 158
Ahmad, S. F., Ansari, M. A., Zoheir, K. M. A., Bakheet, S. A., Korashy, H. M., Nadeem, A., Ashour, A. E., & Attia, S. M. (2015) · Immunobiology · doi:10.1016/j.imbio.2015.01.008 · Cited by 112
Old and new therapeutics for Rheumatoid Arthritis: in vivo models and drug development
Sardar, S., & Andersson, Å. (2016) · Immunopharmacology and Immunotoxicology · doi:10.3109/08923973.2015.1125917 · Cited by 50
Pathogenesis of bone lesions in rheumatoid arthritis.
Goldring, S. R., & Gravallese, E. M. (2002) · Current Rheumatology Reports · doi:10.1007/s11926-002-0069-y · Cited by 44
Metadata
- Authors
- Joosten, L. A. B., Helsen, M. M. A., Saxne, T., van de Loo, F. A. J., Heinegård, D., & van den Berg, W. B.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 1999-11-01
- Volume
- 163
- Issue
- 9
- Pages
- 5049-5055
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W4313347845
- Cited by
- 405
- References
- 28
- FWCI
- 14.55
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.